PT  - JOURNAL ARTICLE
AU  - Christopher Barbour
AU  - Peter Kosa
AU  - Mihael Varosanec
AU  - Mark Greenwood
AU  - Bibiana Bielekova
TI  - Molecular models of multiple sclerosis severity identify heterogeneity of pathogenic mechanisms
AID  - 10.1101/2020.05.18.20105932
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.18.20105932
4099  - http://medrxiv.org/content/early/2020/05/22/2020.05.18.20105932.short
4100  - http://medrxiv.org/content/early/2020/05/22/2020.05.18.20105932.full
AB  - The inability to measure putative pathogenic processes in the central nervous system (CNS) of living subjects precludes the determination of their temporal distribution, intra-individual heterogeneity, and their ability to predict disease course. Using multiple sclerosis (MS) as an example of a complex neurological disorder, we sought to determine if cerebrospinal fluid (CSF) biomarkers can be aggregated to predict future rates of MS progression and provide molecular insight into mechanisms of CNS destruction. 1,305 CSF biomarkers were analyzed blindly in the longitudinal training dataset (N=129) of untreated MS patients, using DNA-aptamer assay. Random forest models, validated in an independent longitudinal cohort (N=64), uncovered signatures of MS severity, measured by clinical scales and volumetric brain imaging. Cluster analysis revealed intra-individual molecular heterogeneity of disease mechanisms that include both CNS- and immune-related pathways and may represent novel targets for inhibiting MS progression.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT00794352Funding StatementThis study was funded by the Intramural Research Program of the National Institute Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data will be available upon publishing of the peer-reviewed manuscript.